Tricycles, their manufacture and use as pharmaceutical agents
AssigneeHoff Hoffmann-La Roche Inc.
InventorsGeorges Guy, Bernhard Goller, Hans-Willi Krell, Klaus-Peter Kuenkele, Anja Limberg, Petra Rueger, Matthias Rueth
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
Claims16
A method of treating a patient having a hyperproliferative disease which comprises treating said patient with a therapeutically effective amount of a compound according to formula I
- wherein
- R1 is hydrogen, alkyl, or —C(O)-alkyl;
- R2 is hydrogen, alkyl, cyano or halogen;
- R3 is hydrogen, alkyl, (C3-C6)-cycloalkyl, alkoxy or alkylsulfanyl;
- X is —C(O)— or —CH2—;
- Y is —NH—, —CH2—CR4R5—, —CR4R5—CH2— or —CR4R5—;
- wherein
- R4 is hydrogen or alkyl;
- and
- R5 is hydrogen or alkyl,
- or alternatively
- R4 and R5 form together with the carbon atom to which they are attached a cycloalkyl ring;
- and all pharmaceutically acceptable salts thereof.
A compound of formula I,
- wherein
- R1 is alkyl or —C(O)-alkyl;
- R2 is hydrogen, alkyl, cyano or halogen;
- R3 is hydrogen, alkyl, (C3-C6)-cycloalkyl, alkoxy or alkylsulfanyl;
- X is —C(O)— or —CH2—;
- Y is —NH—, —CH2—CR4R5—, —CR4R5—CH2— or —CR4R5—;
- wherein
- R4 is hydrogen or alkyl;
- and
- R5 is hydrogen or alkyl,
- or alternatively
- R4 and R5 form together with the carbon atom to which they are attached a cycloalkyl ring;
- and all pharmaceutically acceptable salts thereof.
A process for the preparation of the compounds of the formula
- wherein
- R1 is alkyl or —C(O)-alkyl;
- R2 is hydrogen, alkyl, cyano or halogen;
- R3 is hydrogen, alkyl, (C3-C6)-cycloalkyl, alkoxy or alkylsulfanyl;
- X is —C(O)— or —CH2—;
- Y is —NH—, —CH2—CR4R5—, —CR4R5—CH2— or —CR4R5—;
- wherein
- R4 is hydrogen or alkyl;
- and
- R5 is hydrogen or alkyl,
- or alternatively
- R4 and R5 form together with the carbon atom to which they are attached a cycloalkyl ring;
- which comprises
- a) reacting a compound of formula II
- wherein R1 is alkyl or —C(O)-alkyl and X and Y have the significance given above for formula I;
- with a compound of formula III,
- wherein A is —OH, —Cl, —H or —OMe and R2 and R3 have the significance given above for formula I;
- to give the compounds of formula I,
- wherein R1 is alkyl or —C(O)-alkyl and R2, R3, X and Y have the significance given above for formula I;
- b) isolating said compound of formula I from the reaction mixture, and
- if desired, converting it into a pharmaceutically acceptable salt.
A pharmaceutical composition comprising a compound of formula I
- wherein
- R1 is alkyl or —C(O)-alkyl;
- R2 is hydrogen, alkyl, cyano or halogen;
- R3 is hydrogen, alkyl, (C3-C6)-cycloalkyl, alkoxy or alkylsulfanyl;
- X is —C(O)— or —CH2—;
- Y is —NH—, —CH2—CR4R5—, —CR4R5—CH2— or —CR4R5—;
- wherein
- R4 is hydrogen or alkyl;
- and
- R5 is hydrogen or alkyl,
- or alternatively
- R4 and R5 form together with the carbon atom to which they are attached a cycloalkyl ring;
- and all pharmaceutically acceptable salts thereof
- together with a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.